Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761655 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL916010 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL589886 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14134551 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9917631 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24974550 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12081887 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22444953 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21224008 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31671113 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131017-A1 | CD22 ANTIBODY AND DRUG CONJUGATES AND USES THEREOF | MEDIMMUNE LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4601705-B1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| EP-4593885-B1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4601703-B1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4601704-B1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4694936-A1 | STEAP2 ANTIBODY DRUG CONJUGATES AND USES THEREOF | MedImmune, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3700578-B1 | SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-2029554-B1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | MEDIBEACON LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130116432-A1 | MODIFIED MACROMOLECULE | STARPHARMA PTY LTD (AU) | 2013-05-09 | — | — | US | disclosed |
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | BIOZONE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120100078-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MALLINCKRODT LLC (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120071402-A1 | Protease Stabilized, Pegylated Insulin Analogues | NOVO NORDISK A/S (DK) | 2012-03-22 | — | — | US | disclosed |
| US-8115000-B2 | Pyrazine derivatives and uses thereof in renal monitoring | MALLINCKRODT LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110319591-A1 | PEGYLATED, EXTENDED INSULINS | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MEDIBEACON INC. | 2009-08-06 | — | — | US | disclosed |
| EP-2029554-A1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | Mallinckrodt, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007149479-A1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | MALLINCKRODT INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131017-A1 | CD22 ANTIBODY AND DRUG CONJUGATES AND USES THEREOF | CD22, CD2, CD2BP2 | HPGD 4627/4885HTT 2173/4885SMN1; SMN2 2135/4885 |
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | LIPA, CETP, DGAT2 | HPGD 1315/4885HTT 2799/4885SMN1; SMN2 4645/4885 |
| US-20110319591-A1 | PEGYLATED, EXTENDED INSULINS | IAPP, IGF1R, INSR | HPGD 4282/4885HTT 1103/4885SMN1; SMN2 1151/4885 |
| US-20120100078-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | CYP3A5, GLS, XDH | HPGD 204/4885HTT 4425/4885SMN1; SMN2 3974/4885 |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | GLS, CYP3A5, PYCR1 | HPGD 185/4885HTT 4204/4885SMN1; SMN2 3945/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | HPGD 2016/4885HTT 1407/4885SMN1; SMN2 4135/4885 |
| US-20120071402-A1 | Protease Stabilized, Pegylated Insulin Analogues | IDE, IAPP, IGFBP4 | HPGD 3590/4885HTT 1511/4885SMN1; SMN2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.